Advertisement

Effects of Nifedipine on Blood Pressure, Arterial Compliance and Left Ventricular Mass in Elderly Patients with Isolated Systolic Hypertension

  • Salvatore Novo
  • Emilio Nardi
  • Giovanni Noto
  • Giuseppe Licata
  • Antonio Strano
Conference paper

Summary

The aim of this study was to evaluate the effects of acute and chronic administration of slow-release nifedipine (SRN) on blood pressure (BP), aortic index (AI), average wall stress (AWS), left ventricular mass (LVM), and other hemodynamic parameters in elderly patients with isolated systolic hypertension (ISH) (systolic blood pressure [SBP] > 175 mmHg). We studied 10 patients (mean age 73.7 ± 5.6 years) in which after a washout period, in basal conditions, 3 h after the administration of SRN (20 mg), and 180 days after chronic therapy (40 mg daily), we evaluated the changes of BP, HR, AI, AWS, LVM, and other parameters obtained by means of echocardiography. After SRN we observed a significant decrease of SBP both in acute (P < 0.005 in supine and P < 0.0125 in upright position) and in chronic (P < 0.0005 in supine and P < 0.005 in upright position) therapies and a slight decrease of DBP, whereas HR did not show great changes. AI decreased significantly (P < 0.01 in acute and in chronic) as well as did systemic vascular resistance (P < 0.025 in acute and P < 0.01 in chronic). Moreover, we observed a significant diminution of AWS (P < 0.01) and LVM (P < 0.01) after 180 days of treatment. These results seem to show that SRN is useful in elderly patients with ISH, because it produces an improvement both of arterial compliance and of left ventricle function parameters.

Keywords

Systolic Blood Pressure Calcium Antagonist Systolic Hypertension Arterial Compliance Shorten Fraction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kannel WB, Gordon T (1978) Evaluation of cardiovascular risk in the elderly: The Framingham Study. Bull NY Acad Med 54: 573–591Google Scholar
  2. 2.
    Subcommittee on Risk Factors and Stroke of the Stroke Council (1987) Risk factors in stroke. AHA Focus Series. American Heart Association. Stroke 3 (1): 9–14Google Scholar
  3. 3.
    Kannel WB, Dauber TR, McGee DL (1980) Perspectives on systolic hypertension: The Framingham Study. Circulation 61: 1179–1182PubMedCrossRefGoogle Scholar
  4. 4.
    Simon ACh. Safer ME, Levenson JA, London GM, Levy BI, Chau NPh (1979) An evaluation of large arteries compliance in man. AM J Physiol 237: 550–554Google Scholar
  5. 5.
    Safar ME, Laurent St, Asmar RE, Savafian A, London GM (1987) Systolic hypertension in patients with arteriosclerosis obliterans of the lower limbs. Angiology 4: 287–295CrossRefGoogle Scholar
  6. 6.
    Ben-Ishay D, Leibel B, Stessman J (1986) Calcium channel blockers in the management of hypertension in the elderly. Am J Med 81 (Suppl VIA): A30–34PubMedCrossRefGoogle Scholar
  7. 7.
    Anonymous (1985) Treatment of hypertension in the over-60s. Lancet 1: 1369–1370 (editorial)Google Scholar
  8. 8.
    Laragh JH, Bühler FR, Chobanian A, Hansson L, Zachariah PK (1987) Calcium antagonists in hypertension: update 1986. J Cardiovasc Pharmacology 9 (Suppl IV): 1–3Google Scholar
  9. 9.
    Zanchetti A (1987) Role of calcium antagonists in systemic hypertension. Am J Cardiol 59: 130–136CrossRefGoogle Scholar
  10. 10.
    Strano A, Novo S, Modica R, Nardi E, Donia G (1986) Hemodynamic effects of acute administration of slow-release nifedipine in elderly patients with systolic hypertension. Am J Nephrol 6 (Suppl I): 91–94PubMedCrossRefGoogle Scholar
  11. 11.
    MacGregor GA (1986) Hypertension. In: Krebs R (ed) Treatment of cardiovascular diseases by Adalat (nifedipine). Schattauer, Stuttgart New York, pp 231–258Google Scholar
  12. 12.
    Kirkendall WM, Burton AC, Epstein FH, Fresis ED (1967) Recomendations for human blood pressure determination by sphygmomanometer. Circulation 36: 980–987PubMedCrossRefGoogle Scholar
  13. 13.
    Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) Recomendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072–1083PubMedCrossRefGoogle Scholar
  14. 14.
    Quinones MA, Pickering E, Alexander JK (1978) Percentage of shortening of the echocardiographic left ventricular dimension. Its use in determining ejection fraction and stroke volume. Chest 74: 59–65PubMedCrossRefGoogle Scholar
  15. 15.
    Eaton LW, Maughan WL, Shoukas AA, Weiss JL (1979) Accuration volume determination in the isolated ejecting canine left ventricle by two-dimensional echocardiography. Circulation 60: 320–327PubMedCrossRefGoogle Scholar
  16. 16.
    Tarazi RC, Magrini F, Dustan HP (1975) The role of aortic distensibility in hypertension. In: Miller P, Safar MD (eds) International symposium on hypertension. Boehringer Ingelheim, Monaco, pp 133–138Google Scholar
  17. 17.
    Novo S, Licata G, Pinto A, Davi G, Strano A (1983) Haemodynamic effects of an antihypertensive combination between labetalol and chlortalidone administered for 6 months. J Hypertens 1 (Suppl II): 353–360Google Scholar
  18. 18.
    Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55: 613–618PubMedCrossRefGoogle Scholar
  19. 19.
    Martin MA, Fieller NRJ (1979) Echocardiography in cardiovascular drug assessment. Br Heart J 41: 536–543PubMedCrossRefGoogle Scholar
  20. 20.
    Simon ACh, Levenson JA, Safar ME (1985) Hemodynamic mechanisms of and therapeutic approach to systolic hypertension. J Cardiovasc Pharmacol 7: 22–27CrossRefGoogle Scholar
  21. 21.
    Fleckenstein A, Frey M, Fleckenstein-Grün G (1986) Antihypertensive and arterial anticalcinotic effects of calcium antagonists. Am J Cardiol 57: 1–10CrossRefGoogle Scholar
  22. 22.
    Fleckenstein A (1988) Future prospects in calcium antagonist therapy: prevention of arteriosclerotic vascular damage. Abstract of Verapamil Satellite Symposium of the 25 Anniversary International Symposium on Calcium Antagonists in Hypertension, Basel, February 9–11, 1988. p3Google Scholar
  23. 23.
    Bouthier JD, DeLuca N, Safar ME, Simon ACh (1985) Cardiac hypertrophy and arterial distensibility in essential hypertension. Am Heart J 109: 1345–1352PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1989

Authors and Affiliations

  • Salvatore Novo
    • 1
  • Emilio Nardi
    • 2
  • Giovanni Noto
    • 2
  • Giuseppe Licata
    • 2
  • Antonio Strano
    • 3
  1. 1.Institute of Chest DiseasesUniversity of CataniaCataniaItaly
  2. 2.Institute of Clinical MedicineUniversity of PalermoPalermoItaly
  3. 3.Department of Internal MedicineII University of RomeTor Vergata, RomeItaly

Personalised recommendations